New York, United States
BeyondSpring, based in Duncan, South Carolina, is a pioneering biotechnology company focused on advancing healthcare. Established in 2010, the company operates within the Biopharma industry, specifically targeting the development of innovative cancer therapies to improve clinical outcomes in both the United States and China.
The company’s flagship development, plinabulin, is positioned as a "pipeline in a drug," with its application both as an anti-cancer agent and for preventing chemotherapy-induced neutropenia (CIN). The DUBLIN-3 Phase 3 study showed promising results in extending overall survival for non-small cell lung cancer patients. The combination of plinabulin with G-CSF has also achieved positive Phase 3 results, earning breakthrough status in the U.S. and China.
BeyondSpring last secured a Series A investment from Fang Fund Partners and Xintong Capital on March 1, 2014. With its robust product pipeline and strategic footprint in major global markets, BeyondSpring presents significant opportunities for prospective investors in the biopharma sector.
